Efficacy of methylene blue in refractory septic shock: study protocol for a multicenter, randomized, placebo-controlled trial

What Was Tested

This clinical study looks at Methylene blue (non-peptide stack partner).

Septic shock is now the leading cause of mortality in intensive care units (ICUs).

This clinical trial has been registered at ChiCTR ( https://www.chictr.org.cn/ ) on March 16, 2023.

Who Took Part

According to the abstract, 100 patients were involved.

The age groups tagged for this paper are adults.

This study is a multicenter, randomized, placebo-controlled trial planning to include 100 refractory septic shock patients.

How the Study Was Run

In design terms this was a randomized, placebo-controlled and multicenter study.

Random assignment meant chance, not the researchers, decided who got Methylene blue (non-peptide stack partner) and who got the comparison, which limits bias.

The comparison arm used a placebo, so changes seen with Methylene blue (non-peptide stack partner) could be set against what happens without it.

More than one site took part, so the patients came from several places.

Secondary outcomes include other hemodynamic parameters, oxygen metabolism indexes, tissue perfusion indexes, major organ function indexes, and certain plasma cytokines and other factors.

What Was Measured

Topics PubMed links to this paper include Arterial Pressure, Hemodynamics, Intensive Care Units, Methylene Blue, Randomized Controlled Trials as Topic, Shock, Septic and Vasoconstrictor Agents.

Author keywords: Septic shock and Study protocol.

What This Means in Plain Language

The paper is a randomized, placebo-controlled and multicenter study of Methylene blue (non-peptide stack partner) in 100 patients.

Its findings take up roughly 4 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2024 (Trials), a journal based in England.

More context: the Methylene blue (non-peptide stack partner) compound page, all human trials.